Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Pregabalin Pfizer, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 10/04/2014, Revision: 13, Status: Authorised
Case Medical Research
doi 10.31525/cmr-6ac6ed
Full Text
Open PDF
Abstract
Available in
full text
Date
June 19, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Pregabalin Accord, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Bronchitol, Mannitol, Cystic Fibrosis, Date of Authorisation: 13/04/2012, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Xyrem, Sodium Oxybate, Cataplexy,Narcolepsy, Date of Authorisation: 13/10/2005, Revision: 29, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Colobreathe, Colistimethate Sodium, Cystic Fibrosis, Date of Authorisation: 13/02/2012, Revision: 10, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Briviact (In Italy: Nubriveo), Brivaracetam, Epilepsy, Date of Authorisation: 13/01/2016, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): PritorPlus, Telmisartan / Hydrochlorothiazide, Hypertension, Date of Authorisation: 22/04/2002, Revision: 33, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Levetiracetam Sun, Levetiracetam, Epilepsy, Date of Authorisation: 14/12/2011, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Raloxifene Teva, Raloxifene, Osteoporosis, Postmenopausal, Date of Authorisation: 29/04/2010, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Imbruvica, Ibrutinib, Lymphoma, Mantle-Cell,Leukemia, Lymphocytic, Chronic, B-Cell, Date of Authorisation: 21/10/2014, Revision: 13, Status: Authorised
Case Medical Research
